Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 201335 NA DDI Study with Probe Cocktail
NCT02182336Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, open-label, single-arm trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the curve (AUC) 0-24h of caffeine at Day 19, Area under the curve (AUC) 0-120h of Warfarin at Day 19 and 5 more. Started Jun 2008; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182336.